• Cyclodextrin-Coated Magnetic Nanoparticles for Uremic Toxin

  2026-08-05

  This study presents a systematic evaluation of cyclodextrin-functionalized magnetic nanoparticles for the adsorption of protein-bound uremic toxins relevant to chronic kidney disease. The work highlights the physicochemical factors that govern toxin capture, with implications for next-generation blood purification materials.

• RESTRICT-seq Reveals KAT6A/B as Epigenetic Dependencies in S

  2026-08-05

  The reference study introduces RESTRICT-seq, a time-gated CRISPR screening method that uncovers novel epigenetic regulators sustaining squamous cell carcinoma (SCC) resistance. By identifying KAT6A and KAT6B as critical dependencies, the work highlights new avenues for targeted senescence induction and epigenetic therapy in cancer biology.

• TPCA-1 (SKU A4602): Reliable IKK-2 Inhibition for Inflammati

  2026-08-04

  This article delivers an evidence-based, scenario-driven guide to addressing common laboratory challenges in inflammation and cell viability assays using TPCA-1 (SKU A4602). Drawing on quantitative data, recent literature, and workflow insights, it demonstrates how this selective IKK-2 inhibitor from APExBIO ensures reliable inhibition of the NF-κB pathway, supporting both experimental reproducibility and advanced disease modeling.

• O-GlcNAcylation Links Wnt Signaling to Glycolytic Bone Forma

  2026-08-04

  This study reveals that O-GlcNAcylation is essential for Wnt-driven bone formation by directly regulating glycolytic metabolism in osteoblasts. The findings clarify a previously unknown post-translational mechanism behind Wnt-induced osteogenesis, providing new insights for targeting skeletal diseases.

• Rethinking Amikacin Sulfate: Precision Delivery for NTM Rese

  2026-08-03

  This thought-leadership article examines how Amikacin Sulfate is redefining the translational research landscape for non-tuberculous mycobacterial (NTM) infections. Integrating mechanistic insights, in vitro and in vivo data, and the latest targeted delivery strategies, we explore how researchers can harness this aminoglycoside antibiotic for advanced intracellular infection models, while minimizing systemic toxicity. Strategic guidance is provided for protocol optimization, experimental design, and positioning within the evolving competitive field of antimicrobial therapeutics.

• Novel Allosteric PDK4 Inhibitors: Implications for Metabolic

  2026-08-03

  This study identifies a new class of potent, orally bioavailable allosteric PDK4 inhibitors, with compound 8c displaying strong activity in metabolic, allergic, and cancer models. The research advances understanding of PDK4 as a therapeutic target and provides a scaffold for future drug development.

• Angiotensin II Drives M1 Macrophage Polarization via Cx43/NF

  2026-08-02

  This study reveals that angiotensin II promotes pro-inflammatory M1 polarization in RAW264.7 macrophages through the connexin 43/NF-κB signaling axis. Inhibiting Cx43 hemichannels with selective agents such as Gap19 suppresses this polarization, highlighting a mechanistic target for inflammation modulation in cardiovascular and neuroinflammatory research.

• Antipyrine (SKU B1886): Reliable Benchmark for CNS Assays

  2026-08-01

  This article addresses common laboratory challenges in cell viability, proliferation, and blood-brain barrier (BBB) assays by illustrating the advantages of Antipyrine (SKU B1886) from APExBIO. Drawing on recent high-throughput permeability modeling and validated best practices, it guides researchers to reproducible, data-driven results using this analytically pure, versatile compound.

• Acetoacetic Acid Sodium Salt: Next-Gen Metabolic Pathway Ana

  2026-07-31

  Explore how acetoacetic acid sodium salt advances metabolic pathway research and diabetes studies. Uncover new insights into sodium 3-oxobutanoate’s role, protocol best practices, and assay innovation.

• MG-132 in Translational Research: Mechanistic Leverage & Str

  2026-07-31

  Explore how MG-132 (Z-LLL-al) empowers translational researchers to dissect ubiquitin-proteasome system dynamics, optimize apoptosis and cell cycle arrest assays, and advance mechanistic understanding in cancer and neurological disease models. This thought-leadership article bridges evidence-based protocol design, recent findings on autophagy and proteostasis, and actionable guidance for workflow innovation.

• Ferrostatins Target Lipid Peroxidation in Disease Models

  2026-07-30

  The referenced study establishes ferrostatin-1 as a selective inhibitor of ferroptosis—a regulated, oxidative, nonapoptotic cell death pathway—by blocking lipid peroxidation across diverse cellular and disease models. These findings clarify the mechanistic role of lipid ROS in cell death and highlight new directions for oxidative injury research and antioxidant screening.

• Angiotensin 1/2 (2-7): Advanced Insights into RAS Peptide Fu

  2026-07-30

  Explore the advanced mechanistic and translational roles of Angiotensin 1/2 (2-7) peptide in blood pressure regulation and viral pathogenesis research. This article offers a unique, protocol-driven, and evidence-grounded resource for researchers.

• Advancing mRNA Delivery: Dual-Fluorescence Tools for Transla

  2026-07-29

  A deep dive into the mechanistic and strategic advantages of EZ Cap™ Cy5 EGFP mRNA (5-moUTP) for translational researchers, outlining how dual-fluorescent, chemically optimized mRNA reporters are redefining standards in gene delivery, immune evasion, and functional genomics. Drawing on cutting-edge evidence and workflow integration, this article articulates a forward-thinking path for translational teams seeking to accelerate innovation and reproducibility in mRNA delivery and gene regulation studies.

• Fosinopril Sodium: Precision ACE Inhibition in Hypertension

  2026-07-29

  Fosinopril sodium’s unique phosphinic acid structure and dual elimination pathways position it as a next-generation ACE inhibitor for cardiovascular and renal disease modeling. This article unpacks workflow enhancements, troubleshooting strategies, and the translational edge researchers can gain by leveraging APExBIO’s Fosinopril sodium in advanced hypertension studies.

• Copper Supplementation Reduces Hypoxia-Induced Neuronal Ferr

  2026-07-28

  This study demonstrates that copper supplementation can alleviate hypoxia-induced oxidative stress and ferroptosis in neuronal cells, revealing a protective mechanism via the SOD1/GPX4 axis. These findings highlight copper's therapeutic potential in mitigating hypoxic brain injury and inform future research on neuroprotective strategies.

16202 records 1/1081 page Next 12345 下5页 Last page